NASDAQ:VSTM Verastem (VSTM) Stock Price, News & Analysis → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Free VSTM Stock Alerts $9.25 -0.06 (-0.64%) (As of 03:52 PM ET) Add Compare Share Share Today's Range$9.02▼$9.3850-Day Range$9.31▼$13.1252-Week Range$4.26▼$15.18Volume61,747 shsAverage Volume137,077 shsMarket Capitalization$234.12 millionP/E RatioN/ADividend YieldN/APrice Target$28.79 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Verastem alerts: Email Address Verastem MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside212.2% Upside$28.79 Price TargetShort InterestBearish3.94% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.17Based on 6 Articles This WeekInsider TradingSelling Shares$6,619 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.31) to ($2.84) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.04 out of 5 starsMedical Sector422nd out of 907 stocksPharmaceutical Preparations Industry189th out of 422 stocks 3.5 Analyst's Opinion Consensus RatingVerastem has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVerastem has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.94% of the float of Verastem has been sold short.Short Interest Ratio / Days to CoverVerastem has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Verastem has recently increased by 27.09%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVerastem does not currently pay a dividend.Dividend GrowthVerastem does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VSTM. Previous Next 1.6 News and Social Media Coverage News SentimentVerastem has a news sentiment score of -0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Verastem this week, compared to 2 articles on an average week.Search Interest10 people have searched for VSTM on MarketBeat in the last 30 days. This is an increase of 43% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Verastem to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Verastem insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,619.00 in company stock.Percentage Held by InsidersOnly 2.20% of the stock of Verastem is held by insiders.Percentage Held by Institutions88.37% of the stock of Verastem is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Verastem are expected to grow in the coming year, from ($4.31) to ($2.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verastem is -2.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verastem is -2.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerastem has a P/B Ratio of 4.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchMysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. About Verastem Stock (NASDAQ:VSTM)Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.Read More VSTM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VSTM Stock News HeadlinesApril 23, 2024 | americanbankingnews.comVerastem (NASDAQ:VSTM) Share Price Crosses Above 200-Day Moving Average of $9.60April 20, 2024 | investing.comVerastem Oncology appoints new CMO to lead cancer drug trialsApril 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.April 19, 2024 | finance.yahoo.comVerastem, Inc. (VSTM)April 18, 2024 | marketwatch.comVerastem Oncology Names John Hayslip as Chief Medical OfficerApril 18, 2024 | businesswire.comVerastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical OfficerApril 12, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Shattuck Labs (STTK) and Verastem (VSTM)April 10, 2024 | investing.comVerastem CFO sells shares to cover tax obligationsApril 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.April 4, 2024 | businesswire.comVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 27, 2024 | markets.businessinsider.comVerastem’s Strategic Advancements and Financial Stability Underscore Buy RatingMarch 22, 2024 | investing.comVerastem director sells over $8,500 in company stockMarch 20, 2024 | finance.yahoo.comVSTM Apr 2024 11.000 callMarch 19, 2024 | markets.businessinsider.comVerastem: Financial Resilience and Promising Drug Pipeline Despite Short-Term LossesMarch 18, 2024 | businesswire.comGlobal Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian CancerMarch 16, 2024 | finance.yahoo.comVSTM Apr 2024 14.000 callMarch 14, 2024 | benzinga.comRecap: Verastem Q4 EarningsMarch 14, 2024 | investorplace.comVSTM Stock Earnings: Verastem Misses EPS for Q4 2023March 14, 2024 | businesswire.comVerastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business UpdatesMarch 11, 2024 | finance.yahoo.comVerastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet NeedsMarch 11, 2024 | businesswire.comVerastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women's Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet NeedsMarch 10, 2024 | finance.yahoo.comVSTM Mar 2024 2.000 putMarch 6, 2024 | markets.businessinsider.comVerastem Oncology Granted FDA Orphan Drug Designation For Avutometinib In Ovarian CancerMarch 6, 2024 | msn.comVerastem gets FDA orphan drug status for low-grade ovarian cancer therapyMarch 5, 2024 | businesswire.comVerastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian CancerMarch 5, 2024 | businesswire.comVerastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024February 23, 2024 | benzinga.comVerastem Stock (NASDAQ:VSTM), Short Interest ReportSee More Headlines Receive VSTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verastem and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today4/25/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:VSTM CUSIP92337C10 CIK1526119 Webwww.verastem.com Phone(781) 292-4200FaxN/AEmployees73Year FoundedN/APrice Target and Rating Average Stock Price Target$28.79 High Stock Price Target$36.00 Low Stock Price Target$17.50 Potential Upside/Downside+209.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($4.1004) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-87,370,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-127.00% Return on Assets-54.73% Debt Debt-to-Equity Ratio0.70 Current Ratio5.45 Quick Ratio5.45 Sales & Book Value Annual Sales$2.60 million Price / Sales90.63 Cash FlowN/A Price / Cash FlowN/A Book Value$2.27 per share Price / Book4.10Miscellaneous Outstanding Shares25,310,000Free Float24,751,000Market Cap$235.64 million OptionableOptionable Beta0.48 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Daniel W. Paterson (Age 63)President, CEO & Director Comp: $697.98kMr. Daniel Calkins (Age 36)CFO and Principal Accounting & Financial Officer Comp: $1.42MMr. Richard H. Aldrich M.B.A. (Age 70)Founder and Consultant Comp: $38.39kDr. Robert A. Weinberg Ph.D.Co-Founder & Chair of Scientific Advisory BoardDr. Piyush B. Gupta Ph.D.Co-FounderDr. Michelle Dipp M.D. (Age 48)Ph.D., Co-Founder Mr. Robert Pintar M.B.A.Senior Vice President of Technical OperationsDr. Jonathan Pachter Ph.D. (Age 66)Chief Scientific Officer Comp: $238.18kMr. Nate SanburnSenior Vice President of Corporate Development & External EngagementDr. Hagop Youssoufian M.D. (Age 67)M.Sc., Ph.D., Head of Medical Strategy More ExecutivesKey CompetitorsEpizymeNASDAQ:EPZMMerrimack PharmaceuticalsNASDAQ:MACKVanda PharmaceuticalsNASDAQ:VNDARigel PharmaceuticalsNASDAQ:RIGLXOMANASDAQ:XOMAView All CompetitorsInsiders & InstitutionsCannon Global Investment Management LLCBought 11,100 shares on 4/17/2024Ownership: 0.044%Daniel CalkinsSold 6 sharesTotal: $65.22 ($10.87/share)Daniel CalkinsSold 25 sharesTotal: $300.50 ($12.02/share)Daniel CalkinsSold 55 sharesTotal: $608.85 ($11.07/share)Dan PatersonSold 244 sharesTotal: $2,613.24 ($10.71/share)View All Insider TransactionsView All Institutional Transactions VSTM Stock Analysis - Frequently Asked Questions Should I buy or sell Verastem stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verastem in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VSTM shares. View VSTM analyst ratings or view top-rated stocks. What is Verastem's stock price target for 2024? 7 brokerages have issued 12-month price targets for Verastem's stock. Their VSTM share price targets range from $17.50 to $36.00. On average, they anticipate the company's stock price to reach $28.79 in the next year. This suggests a possible upside of 212.2% from the stock's current price. View analysts price targets for VSTM or view top-rated stocks among Wall Street analysts. How have VSTM shares performed in 2024? Verastem's stock was trading at $8.14 at the start of the year. Since then, VSTM stock has increased by 13.3% and is now trading at $9.22. View the best growth stocks for 2024 here. Are investors shorting Verastem? Verastem saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 806,400 shares, an increase of 27.1% from the March 31st total of 634,500 shares. Based on an average daily volume of 144,200 shares, the days-to-cover ratio is currently 5.6 days. Currently, 3.9% of the company's shares are sold short. View Verastem's Short Interest. When is Verastem's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our VSTM earnings forecast. How were Verastem's earnings last quarter? Verastem, Inc. (NASDAQ:VSTM) released its quarterly earnings data on Thursday, March, 14th. The biopharmaceutical company reported ($1.02) EPS for the quarter, missing analysts' consensus estimates of ($0.82) by $0.20. When did Verastem's stock split? Shares of Verastem reverse split on the morning of Thursday, June 1st 2023. The 1-12 reverse split was announced on Thursday, June 1st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What is Robert Forrester's approval rating as Verastem's CEO? 11 employees have rated Verastem Chief Executive Officer Robert Forrester on Glassdoor.com. Robert Forrester has an approval rating of 100% among the company's employees. This puts Robert Forrester in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Verastem own? Based on aggregate information from My MarketBeat watchlists, some companies that other Verastem investors own include TherapeuticsMD (TXMD), Micron Technology (MU), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (gild), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Amarin (AMRN) and Viking Therapeutics (VKTX). Who are Verastem's major shareholders? Verastem's stock is owned by many different retail and institutional investors. Top institutional shareholders include Cannon Global Investment Management LLC (0.04%). Insiders that own company stock include Brian M Stuglik, Dan Paterson, Daniel Calkins and Robert E Gagnon. View institutional ownership trends. How do I buy shares of Verastem? Shares of VSTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VSTM) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithYour Money is Not SafeAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verastem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
